Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: A pilot study

Pathology Research and Practice

Volumn 207, Issue 3, 2011, Pages 182-187

  Çiriş, Ibrahim Metin ^a   Bozkurt, Kemal Kürşat ^a   Başpinar, Şirin ^a   Kapucuoĝlu, Fatma Nilgün ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Breast cancer; COX 2; HER 2 neu; Immunohistochemistry

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE LOCATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE BREAST CARCINOMA; LYMPH NODE METASTASIS; PILOT STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CHI-SQUARE DISTRIBUTION; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PARAFFIN EMBEDDING; PHENOTYPE; PILOT PROJECTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TURKEY; UP-REGULATION;

EID: 79952440758     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.01.005     Document Type: Article

References (41)

1. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J. 1998, 12:1063-1073.
2. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
3. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3336-3340.
4. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58:362-366.
5. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
6. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19:19-27.
7. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999, 59:4356-4362.
8. Okami J., Yamamoto H., Fujiwara Y., Tsujie M., Kondo M., Noura S., et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin. Cancer Res. 1999, 5:2018-2024.
9. Kokawa A., Kondo H., Gotoda T., Ono H., Saito D., Nakadaira S., et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001, 91:333-338.
10. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999, 59:198-204.
11. Yoshimura R., Sano H., Masuda C., Kawamura M., Tsubouchi Y., Chargui J., et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000, 89:589-596.
12. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001, 7:861-867.
13. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999, 59:991-994.
14. Shono T., Tofilon P.J., Bruner J.M., Owolabi O., Lang F.F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001, 61:4375-4381.
15. Bennett A., Charlier E.M., McDonald A.M., Simpson J.S., Stamford I.F., Zebro T. Prostaglandins and breast cancer. Lancet 1977, 2:624-626.
16. Rolland P.H., Martin P.M., Jacquemier J., Rolland A.M., Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 1980, 64:1061-1070.
17. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 2001, 276:18563-18569.
18. Zhao Y., Agarwal V.R., Mendelson C.R., Simpson E.R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137:5739-5742.
19. Parrett M.L., Harris R.E., Joarder F.S., Ross M.S., Clausen K.P., Robertson F.M. Cyclooxygenase-2 expression in human breast cancer. Int. J. Oncol. 1997, 10:503-507.
20. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 1998, 90:455-460.
21. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89:2637-2645.
22. Half E., Tang X.M., Gwyn K., Sahin A., Wathen K., Sinicrope F.A. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002, 62:1676-1681.
23. Ristimaki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62:632-635.
24. Denkert C., Winzer K.-J., Muller B.-M., Weichert W., Pest S., Kobel M., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease survival and overall survival in patients with breast cancer. Cancer 2003, 97:2978-2987.
25. Spizzo G., Gastl G., Wolf D., Gunsilius E., Steurer M., Fong D., et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br. J. Cancer 2003, 88:574-578.
26. Watanabe O., Shimizu T., Kinoshita J., Utada Y., Okabe T., Kimura K., et al. Expression of cyclooxygenase-2 in malignant and benign breast tumours. Anticancer Res. 2003, 23:3215-3221.
27. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash., DC) 1987, 235:177-182.
28. Klapper L.N., Kirschbaum M.H., Sela M., Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 2000, 77:25-79.
29. Vadlamudi R., Mandal M., Adam L., Steinbach G., Mendelson J., Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999, 18:305-314.
30. Carter D., Connolly J., Ellis I.O., et al. Consensus conference on the classification of ductal carcinoma in situ. Hum. Pathol. 1997, 28:1221-1225.
31. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
32. Lee A.H.S., Ellis I.O. The Nottingham Prognostic Index for invasive carcinoma of the breast. Pathol. Oncol. Res. 2008, 14:113-115.
33. Shim V., Gauthier M.L., Sudilovsky D., Mantei K., Chew K.L., Moore D.H., et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 2003, 63:2347-2350.
34. Shamma A., Yamamoto H., Doki Y., Okami J., Kondo M., Fujiwara Y., et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 2000, 6:1229-1238.
35. Rosai J. Breast. Rosai and Ackerman's Surgical Pathology 2004, 1763-1876. Mosby, New York. 9th ed. J. Rosai (Ed.).
36. Boland G.P., Butt I.S., Prasad R., Knox W.F., Bundred N.J. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br. J. Cancer 2004, 90:423-429.
37. Witton C.J., Hawe S.J.K., Cooke T.G., Bartlett J.M.S. Cyclooxygenase 2 (COX-2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004, 45:47-54.
38. Costa C., Soares R., Reis-Filho J.S., Leitao D., Amendoeira I., Schmitt F.C. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J. Clin. Pathol. 2002, 55:429-434.
39. Subbaramaiah K., Norton L., Gerald W., Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 2002, 277:18649-18657.
40. Zeeneldin A.A., Mohamed A.M., Abdel H.A., Taha F.M., Goda I.A., AboDeef W.T. Survival effects of cyclooxygenase-2 and 12-lypooxygenase in Egyptian women with operable breast cancer. Indian J. Cancer 2009, 46:54-60.
41. Howe L.R., Subbaramaiah K., Patel J., Masferrer J.L., Deora A., Hudis C., et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002, 62:5405-5407.